Find Funding Opportunities

COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements
NINDS Interest in Pain Research | View information, FAQs, resources, and available funding notices and opportunities.

All NINDS-related funding opportunity announcements (FOAs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed.Search the Closed Announcements tab to find expired opportunities. Search the Notices tab to find all Notices.

Learn more about award types and program directors and managers.

NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!

Expiration Date: Friday, October 14, 2022FOA Number: RFA-HL-23-015Release Date: Thursday, July 7, 2022Announcement Type: RFA
The purpose of the initiative is to utilize the cohort study design to address key population research gaps in the health of Asian Americans (AsA), Native Hawaiians, and Pacific Islanders (NHPI). This FOA is for clinical/community field centers (CCFCs), and a companion one will solicit for the coordinating center (CC).
Expiration Date: Friday, October 7, 2022FOA Number: RFA-HL-23-019Release Date: Thursday, July 7, 2022Announcement Type: RFA
The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (U01) applications to support investigator- initiated clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of in-depth product characterization, manufacturing, potency, identity, quality, safety, in vivo function and integration, or effectiveness. Toward these ends, the NIH will consider applications for late-stage preclinical research studies involving adult stem cells in the context of generating or supplementing the necessary evidence for clinical development, including, but not limited to, the submission of an Investigational New Drug (IND) or Investigational New Device Exemption (IDE) package; or to support such research conducted under an authorized IND or IDE. Due to the complex nature of requirements in this FOA (e.g., 1:1 matching funds, resource sharing), applicants are strongly encouraged to communicate with the appropriate NIH Scientific/Research Contact and review online Frequently Asked Questions (FAQs) prior to submitting an application. Staff will be able to advise applicants in determining if their research meets the requirements and objectives of this FOA.
Expiration Date: Friday, October 14, 2022FOA Number: RFA-HL-23-016Release Date: Thursday, July 7, 2022Announcement Type: RFA
The purpose of the initiative is to utilize the cohort study design to address key population research gaps in the health of Asian Americans (AsA), Native Hawaiians, and Pacific Islanders (NHPI). This FOA is for the coordinating center (CC), and a companion one will solicit for clinical/community field centers (CCFCs).
Research Category: CounterACTExpiration Date: Friday, October 18, 2024FOA Number: PAR-22-209Release Date: Wednesday, July 6, 2022Announcement Type: PARContact: Shardell Spriggs

This Funding Opportunity Announcement (FOA) solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The overall scope of this solicitation includes validation of therapeutic targets and preclinical characterization of lead compounds. The UG3 phase of this FOA supports target validation and characterization of initial lead compound(s); UH3 phase activities include candidate optimization and in vivo demonstration of activity and efficacy in relevant post-exposure models. At the conclusion of the overall UG3/UH3 funding period, projects are expected to deliver at least one well-characterized therapeutic candidate.

Research Category: Neural Exposome, ONETOXExpiration Date: Thursday, October 6, 2022FOA Number: PAR-22-211Release Date: Tuesday, July 5, 2022Announcement Type: PARContact: David Jett

This Funding Opportunity Announcement (FOA) invites applications for basic and translational research on the impact of the microbiome on Alzheimers Disease and Alzheimers Disease Related Dementias (AD/ADRD). While there is growing evidence that the microbiome is an important factor that contributes to overall health and a variety of diseases and disorders, the role of the alimentary canal and other sources of endogenous microbiota in specific AD/ADRDs has not been adequately addressed. This FOA will support mechanistic research focused on a more rigorous in-depth examination of the potential interactions between the microbiome and genetic and non-genetic molecular targets that influence AD/ADRD. It is expected that these studies will address the clinical relevance of the microbiome on disease initiation, progression, or modification, and will lead ultimately to better therapeutic interventions.

Expiration Date: Saturday, October 1, 2022FOA Number: RFA-AR-23-001Release Date: Tuesday, June 28, 2022Announcement Type: RFA
The purpose of this initiative is to solicit applications for Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers. These Centers promote collaborative basic, translational, and clinical research, and provide important resources that can be used by the national muscular dystrophy research community. The Centers also provide outstanding environments for the training of new scientists electing to pursue careers conducting research in high priority areas of muscular dystrophy. Furthermore, Center investigators participate in community outreach efforts to increase awareness and convey the importance and implications of their research activities to the patient and advocacy communities.
Expiration Date: Saturday, October 8, 2022FOA Number: PAR-22-208Release Date: Monday, June 27, 2022Announcement Type: PAR
The purpose of the FOA is to support the structural characterization of protein species associated with Alzheimer's Disease Related Dementias (ADRDs) through the utilization of cryo-electron microscopy (cryo-EM) and cryo-electron tomography (cryo-ET) of proteins expressed in human tissue and cell sources. Studies in response to this RFA should also include the development of research tools and resources to further characterize/validate the protein species. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2019 update to the National Plan to Address Alzheimer's Disease.
Expiration Date: Saturday, September 6, 2025FOA Number: PAS-22-196Release Date: Tuesday, June 21, 2022Announcement Type: PAS
This Funding Opportunity Announcement (FOA) invites applications to the National Institute on Aging's (NIA) Small Business Innovation Research (SBIR) program. The aim of this FOA is to support research that may lead to the development of innovative products and/or services that have the potential to advance progress in preventing and treating Alzheimer's disease (AD) and AD-related dementias (ADRD) and/or caring for and treating patients living with AD/ADRD.
Expiration Date: Saturday, September 6, 2025FOA Number: PAS-22-197Release Date: Tuesday, June 21, 2022Announcement Type: PAS
This Funding Opportunity Announcement (FOA) invites applications to the National Institute on Aging's (NIA) Small Business Technology Transfer Research (STTR) program. The aim of this FOA is to support research that may lead to the development of innovative products and/or services with the potential to advance progress in preventing and treating Alzheimer's disease (AD) and AD-related dementias (ADRD) and/or caring for and treating patients living with AD/ADRD.
Expiration Date: Friday, September 16, 2022FOA Number: RFA-NS-23-001Release Date: Thursday, June 16, 2022Announcement Type: RFA
The purpose of this funding opportunity announcement (FOA) is to solicit applications for pragmatic clinical trials to decrease or prevent negative clinical outcomes due to vascular contributions to cognitive impairment and dementia (VCID), including locally representative NIH defined populations that experience health disparities in dementia. Examples of responsive projects and interventions that affect VCID outcomes include, but are not limited to, blood pressure control implementation; lifestyle modification using aerobic exercise; and early detection and treatment of VCID risk factors.